It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
HIF-1α, an essential transcription factor under hypoxic condition, is indispensable for chondrocytes during skeletal development but its expression and roles in articular chondrocytes are yet to be revealed. We examined HIF-1α protein expression and the hypoxic condition during mouse osteoarthritis (OA) development using state of the art hypoxic probes and found that its expression decreased as OA progressed, coinciding with the change in hypoxic conditions in articular cartilage. Gain- and loss-of-function of HIF-1α in cell culture experiments showed that HIF-1α suppressed catabolic genes such as Mmp13 and Hif2a. We confirmed these anticatabolic effects by measuring glycosaminoglycan release from wild type and conditional knock-out mice femoral heads cultured ex vivo. We went on to surgically induce OA in mice with chondrocyte-specific deletion of Hif1a and found that the development of OA was exacerbated. Increased expression of catabolic factors and activation of NF-κB signalling was clearly evident in the knock-out mice. By microarray analysis, C1qtnf3 was identified as a downstream molecule of HIF-1α, and experiments showed it exerted anti-catabolic effects through suppression of NF-κB. We conclude that HIF-1α has an anti-catabolic function in the maintenance of articular cartilage through suppression of NF-κB signalling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Sensory & Motor System Medicine, The University of Tokyo, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
2 Sensory & Motor System Medicine, The University of Tokyo, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); Bone and Cartilage Regenerative Medicine, The University of Tokyo, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
3 Bone and Cartilage Regenerative Medicine, The University of Tokyo, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
4 Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
5 Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
6 Drug Discovery Initiative, The University of Tokyo, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)